Literature DB >> 31821545

Integrated cancer networks improve compliance with national guidelines and outcomes for resectable gastric cancer.

Cornelius A Thiels1, Kristine T Hanson1, Elizabeth B Habermann1,2,3, Judy C Boughey2,4, Travis E Grotz2,4.   

Abstract

BACKGROUND: National Comprehensive Cancer Network (NCCN) guidelines recommend accurate clinical staging, perioperative therapy, and complete lymphadenectomy for patients with stage II to III gastric cancer. However, national compliance remains low. It was hypothesized that integrated cancer networks might improve compliance and outcomes within the community.
METHODS: Patients with stage II to III gastric adenocarcinoma undergoing curative-intent resection (National Cancer Data Base, 2006-2015) were examined. Guideline compliance was defined as any perioperative adjunctive therapy, complete lymphadenectomy, complete clinical staging, and complete compliance (all measures). Univariate comparisons and multivariable regression were used to assess factors associated with compliance, and Kaplan-Meier analysis was used to assess survival.
RESULTS: There were 27,210 patients identified: 7235 (26.6%) underwent surgery alone, whereas 19,975 (73.4%) received additional therapy. Half (53.1%) had complete lymphadenectomies, whereas complete clinical staging was available for 65.5%. Overall compliance with all 3 measures was 30.1%. Compliance improved by approximately 20% for each measure across the 10-year study period. Although patients treated at academic programs were most likely to receive concordant care in an adjusted analysis, those treated at integrated care networks were more likely to receive guideline-concordant care (odds ratio [OR], 0.69) than those treated at comprehensive community programs (OR, 0.48) or community programs (OR, 0.45; all P values <.001). The median overall survival was 45.5 months for patients who received guideline-concordant care and 32.0 months for those who did not (P < .001, reference for all ORs: academic programs).
CONCLUSIONS: Compliance with guidelines was associated with improved outcomes. Although the rate of compliance with NCCN guidelines is improving, integrated care networks may be an important way of improving the quality of gastric cancer care within the community.
© 2019 American Cancer Society.

Entities:  

Keywords:  compliance; gastric cancer; national guidelines; neoadjuvant; preoperative therapy; staging

Year:  2019        PMID: 31821545     DOI: 10.1002/cncr.32660

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Guideline adherence and implementation of tumor board therapy recommendations for patients with gastrointestinal cancer.

Authors:  Alina Krause; Gertraud Stocker; Ines Gockel; Daniel Seehofer; Albrecht Hoffmeister; Hendrik Bläker; Timm Denecke; Regine Kluge; Florian Lordick; Maren Knödler
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-08       Impact factor: 4.553

2.  Use of Palliative Interventions at End of Life for Advanced Gastrointestinal Cancer.

Authors:  Vivi W Chen; Jorge I Portuondo; Zara Cooper; Nader N Massarweh
Journal:  Ann Surg Oncol       Date:  2022-08-10       Impact factor: 4.339

3.  Regional Patterns of Hospital-Level Guideline Adherence in Gastric Cancer: An Analysis of the National Cancer Database.

Authors:  Sarah R Kaslow; Leena Hani; Greg D Sacks; Ann Y Lee; Russell S Berman; Camilo Correa-Gallego
Journal:  Ann Surg Oncol       Date:  2022-09-19       Impact factor: 4.339

4.  Patterns and Impact of Fragmented Care in Stage II and III Gastric Cancer.

Authors:  Kristen E Rhodin; Vignesh Raman; Austin Eckhoff; Annie Liu; John Creasy; Daniel P Nussbaum; Dan G Blazer
Journal:  Ann Surg Oncol       Date:  2022-06-20       Impact factor: 4.339

5.  Adherence to guidelines at the patient- and hospital-levels is associated with improved overall survival in patients with gastric cancer.

Authors:  Sarah R Kaslow; Zhongyang Ma; Leena Hani; Katherine Prendergast; Gerardo Vitiello; Ann Y Lee; Russell S Berman; Judith D Goldberg; Camilo Correa-Gallego
Journal:  J Surg Oncol       Date:  2022-04-26       Impact factor: 2.885

6.  The Impact of Commission on Cancer Accreditation Status, Hospital Rurality and Hospital Size on Quality Measure Performance Rates.

Authors:  Mary C Schroeder; Xiang Gao; Ingrid Lizarraga; Amanda R Kahl; Mary E Charlton
Journal:  Ann Surg Oncol       Date:  2022-01-23       Impact factor: 4.339

7.  Gastric Cancer Treatments and Survival Trends in the United States.

Authors:  Kelly A Stahl; Elizabeth J Olecki; Matthew E Dixon; June S Peng; Madeline B Torres; Niraj J Gusani; Chan Shen
Journal:  Curr Oncol       Date:  2020-12-24       Impact factor: 3.677

8.  Pygo2 as a novel biomarker in gastric cancer for monitoring drug resistance by upregulating MDR1.

Authors:  Dongdong Zhang; Yu Liu; Qiuwan Wu; Yahong Zheng; Natasha Mupeta Kaweme; Zhiming Zhang; Mingquan Cai; Youhong Dong
Journal:  J Cancer       Date:  2021-03-15       Impact factor: 4.207

9.  Superior pancreatic lymphadenectomy with portal vein priority via posterior common hepatic artery approach in laparoscopic radical gastrectomy.

Authors:  Yu-Jia Zhang; Rong-Chao Xiang; Jun Li; Yong Liu; Si-Ming Xie; Liang An; Hua-Lin Li; Gang Mai
Journal:  World J Clin Cases       Date:  2022-02-26       Impact factor: 1.337

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.